2024澳门原料网站-免费完整资料

Be the most trusted biotech company

2021-01-14

Henlius Has Reached an Exclusive License Agreement with Chiome for Antibodies Targeting Human TROP2
2021-01-13

Henlius Daratumumab Biosimilar Received IND Approval from NMPA
2020-12-17

NMPA Has Accepted The NDA of HLX01(Rituximab Injection) for the Treatment of Rheumatoid Arthritis
2020-12-07

Henlius Adalimumab Biosimilar 汉达远® Approved by NMPA
2020-11-20

Henlius Released Phase 3 Study Data of its Bevacizumab Biosimilar HLX04 at ESMO Asia 2020
2020-11-12

The IND Application of Henlius Daratumumab Biosimilar Accepted by NMPA
2020-11-09

First Patient Dosed in Phase 1 Clinical Trial of Henlius Denosumab Biosimilar HLX14
2020-11-06

Henlius ACE2-Fc Fusion Protein HLX71 Received IND Approval from US FDA
2020-10-29

The Results of the Phase 3 Study of Henlius’ Adalimumab Biosimilar HLX03 Presented on EADV 2020